Be in the Room Where Decisions Are Made Fierce Biotech Week attracts senior leaders across biotech and pharma, including: C-suite executives and founders Heads of R&D and Drug Development Clinical & TMF leadership BD&L and corporate strategy teams PR & Communications executives Strategic outsourcing partners This is not a spectator audience. It’s a room of...
From research to regulation, the biotech industry is taking a hit, but drug-development companies continue to press forward, moving important discoveries from the lab bench to the patient bedside. The program will begin with a talk with Ultragenyx CEO Emil Kakkis, the scientist behind the first treatment for an ultra-rare genetic disease, and Ryan Dant, the...
AI is making it possible to simulate clinical trials before they begin using realistic synthetic patient cohorts built from real-world data. In this session, you’ll see how these simulations compare to actual Phase 2 and Phase 3 trial data, and how teams are using them to test protocols, reduce risk, and improve study design faster....
As cell and gene therapy companies navigate the 2026 landscape marked by manufacturing overcapacity, a strategic question is no longer if to outsource, but how. For leaders across MSAT, CMC, and technical operations, the choice between renting, leasing, or building distributed manufacturing capabilities has direct implications for speed to clinic, capital efficiency, and long-term scalability....
Discover how modern integration strategies are enabling companies to bridge critical systems, streamline data flow, and maintain regulatory confidence that supports innovation and compliance, so your systems evolve as fast as your business.
The informed consent process is an ongoing dialogue that helps participants decide, with full understanding, whether to take part in a clinical trial. As generative AI begins to influence how consent documents are created, translated, and delivered, this process is becoming more complex. Join experts in IRB oversight, research ethics, and health literacy to explore...
Accelerate biologics development by enabling rapid access to scalable, production-relevant early-stage material that supports developability assessment and process optimization. This webinar highlights Samsung Biologics’ integrated approach, aligning material generation with cell line development, incorporating early optimization, and leveraging stable expression platforms to deliver consistent, high-quality material with reduced variability. Learn how this streamlined strategy shortens...
Ophthalmic drugs face strict regulations, including USP limits on particulate matter and updated EU GMP Annex 1 requirements for comprehensive Contamination Control Strategies (CCS). These standards emphasize minimizing contamination across packaging, sterilization, and system controls. This webinar explores how these regulations impact real-world development challenges and how purpose-built packaging—featuring low particulates, silicone-free designs, and advanced...
Rapid access to early-stage material is critical for biologics development, especially as molecular complexity increases and timelines expand. Generating scalable, high-quality material early helps streamline developability assessments and process development. In this webinar, Samsung Biologics presents its strategy for early material generation, integrating it with cell line development (CLD), early optimization, and stable expression platforms....
LiB Bay Area Regional Ambassador Pilot kicks off May 14 at Genentech, connecting life sciences professionals & local members. Join Latinos in Bio for the Bay Area kickoff of our Regional Ambassador Pilot, an initiative to grow our West Coast presence and connect Latinx life sciences professionals. This special evening, hosted in partnership with Genentech, will combine casual networking...
